Medication Safety and Monitoring in Mental Health Services: Preventing Physical Harm Through Robust Governance
Medication safety in mental health services is a safeguarding issue as much as a clinical one. Missed blood tests, unmanaged side effects, unclear responsibility for monitoring, and poor follow-up after deterioration can lead to avoidable harm. Within the Risk management, safeguarding and crisis response resources and the wider Mental health service models and pathways collection, commissioners and inspectors expect providers to show operational control: clear monitoring routines, escalation routes, and governance that proves the system works day-to-day. This article sets out a practical medicines safety model that strengthens parity of esteem by treating physical health risk as part of core mental health delivery.
Many providers enhance governance by reviewing how shared accountability operates in multi-agency safeguarding arrangements for mental health care.Where medicines safety breaks down in practice
Medication safety failures tend to arise from predictable operational gaps:
- Unclear ownership for physical health monitoring between provider staff, primary care and specialist services.
- Monitoring treated as “admin” rather than a safety-critical process with timescales and escalation.
- Non-attendance unmanaged (missed blood tests or reviews logged but not pursued).
- Side effects not translated into practical support adjustments (diet, activity, sleep, substance use harm reduction).
- Poor documentation of actions, follow-up and outcomes, leaving no defensible audit trail.
A robust model prevents drift by making monitoring a workflow with prompts, thresholds and closed-loop follow-through.
The medicines safety operating model
1) A monitoring register linked to risk level
Services should maintain a medicines monitoring register (or equivalent structured log) that records: medication type, required monitoring tests/checks, due dates, last completed date, and named responsible person for follow-up. The register should include risk level flags (e.g., higher monitoring frequency for medicines with known metabolic or cardiac risk, or where adherence is unstable).
2) Results-to-action pathway
Monitoring only reduces harm if abnormal findings trigger action. Services need a clear results-to-action pathway that states: who reviews results, what thresholds trigger clinical escalation, and what immediate support adjustments are required. For example, significant weight gain or emerging diabetes indicators should trigger a coordinated plan involving the prescriber/GP and practical support changes.
3) Non-attendance and refusal protocol
People miss blood tests and reviews for common, addressable reasons: anxiety, trauma triggers, transport barriers, mistrust, executive function difficulties, or chaotic lifestyles. A non-attendance protocol should define: how quickly staff rebook, how reasonable adjustments are offered (accompaniment, quieter appointment times), and when escalation is required if monitoring is persistently missed.
4) Medicines reconciliation and interaction awareness
Regular medication reconciliation reduces risk from interactions, duplicate prescribing and confusion about changes. Services should have a routine for confirming medication lists after hospital discharge, crisis episodes or GP changes, and ensuring staff are aware of interaction risks (including with alcohol and substances).
5) Governance: audit, supervision and incident learning
Medicines safety must be governed like any other safeguarding risk: regular audits of monitoring compliance, supervision review of high-risk cases, and learning reviews where harm occurred or nearly occurred. Governance should test whether monitoring leads to action, not just completion.
Operational examples (minimum three)
Operational example 1: Preventing missed metabolic monitoring for antipsychotic medication
Context: A person prescribed an antipsychotic requires regular metabolic monitoring. They have missed two blood test appointments due to anxiety and difficulty travelling, and the service previously recorded “DNA” without follow-up.
Support approach: The provider applies the non-attendance protocol and uses the monitoring register to trigger action.
Day-to-day delivery detail: Staff contact the person the same day as the missed appointment, explore barriers, and offer reasonable adjustments: staff accompaniment, transport support, and rebooking at a quieter time. The due date is updated in the register with a short timescale. If the next appointment is missed, staff escalate to the duty/clinical lead for a risk review and coordinate with primary care to agree next steps. Support staff also implement practical wellbeing actions (diet prompts, gentle activity plan) while awaiting monitoring.
How effectiveness or change is evidenced: The register shows monitoring completed within an agreed timeframe, contact notes evidence adjustments were offered, and outcomes show earlier identification of metabolic issues or reassurance where results are stable.
Operational example 2: Results-to-action for rising diabetes risk indicators
Context: Monitoring identifies rising HbA1c (or similar indicators) and significant weight gain. Historically, results were filed with no coordinated action, and the person deteriorated physically.
Support approach: The service activates the results-to-action pathway with shared accountability.
Day-to-day delivery detail: The clinician/duty lead reviews results, escalates to the prescriber/GP, and agrees a joint plan: medication review consideration, referral to relevant physical health support, and a structured lifestyle support plan delivered by frontline staff. The plan includes weekly check-ins for the first month, practical shopping/meal support, and support to attend follow-up health appointments. Actions and review dates are recorded, and a repeat test is scheduled and tracked.
How effectiveness or change is evidenced: Evidence includes documented escalation to primary care/prescriber, completion of follow-up tests, improved physical health indicators over time, and reduced crisis presentations linked to physical health deterioration.
Operational example 3: Medicines reconciliation after hospital discharge
Context: Following hospital discharge, medication changes are made (dose adjustment, new medicines). Without reconciliation, staff continue old routines and the person experiences side effects and confusion.
Support approach: The provider applies a discharge reconciliation routine within 48–72 hours.
Day-to-day delivery detail: Staff confirm the updated medication list with discharge documentation and (where appropriate) primary care, update the care plan and medication prompts, and monitor for expected side effects. The person receives clear explanations in accessible language. If side effects emerge (e.g., sedation affecting daily functioning), staff escalate via the results-to-action pathway and adjust support temporarily (scheduling, falls risk mitigation, hydration support).
How effectiveness or change is evidenced: Evidence includes accurate medication records, documented side effect monitoring and escalation where needed, and reduced medication-related incidents.
Explicit expectations (mandatory)
Commissioner expectation
Commissioners typically expect robust medicines safety governance: monitoring compliance, clear escalation routes for abnormal results or persistent non-attendance, and evidence that providers prevent avoidable harm. They will look for audit data, action tracking, and outcomes that demonstrate reduced physical health deterioration linked to medicines risk.
Regulator / Inspector expectation (e.g., CQC)
Inspectors typically expect safe medicines management: accurate records, monitoring completed and acted upon, reasonable adjustments to support attendance, and clear oversight. They will examine how the service identifies medicines-related risk, responds to missed monitoring, and evidences learning when errors or near misses occur.
Governance and assurance mechanisms
- Monthly monitoring audit (due/overdue checks, completion rates, escalation actions taken).
- High-risk case review in supervision focusing on results-to-action and adherence barriers.
- Incident learning review for medicines-related harm, with actions tracked and re-audited.
- Quality dashboard reporting monitoring compliance and physical health escalation outcomes.
Medication safety becomes defensible when monitoring is systematic, results trigger action, non-attendance is actively managed, and governance proves the system works consistently—not only when a problem emerges.